Subject Index A Acute pro-myelocytic leukemia Active hexose correlated compound (APML), 67 (AHCC), 412 Adenosine triphosphate (ATP) Activity management, 381–382 infusion, 374 Acupuncture treatment, 385–386 Adjuvant Navelbine International for gastric cancer, 129–130 Trialist Association point injection, 179 (ANITA) vitamin K3 for, 178 trials, 10, 12 prescription one Adriamycin, 52 QImen points, 179 Adverse drug reaction (ADR) Sanyinjiao points, 179 reporting systems, 459 Yanglingquen points, 179 Agosterol A steroids structure, 623 Zhangmen points, 179 Aitong powder, 177 Zusanli point, 179 Ajoene, 466 prescription two See also Garlic Ashi points, 179 Allicin, 466 Baihui points, 179 See also Garlic Ganyu points, 179 Allium sativum, see Garlic Mingmen points, 179 American Joint Commission on Neiguan points, 179 Cancer Sanyinjiao points, 179 tumor/node/metastasis schema, 5 Shenyu points, 179 9-Aminocamptothecin, 404 YangLing points with AML, see Acute myeloid leukemia Chinese traditional medicines (AML) injections, 178 Amrita, see Tinospora glabra Zi wu liu zhu principle, 178 Anacarcin Forte, 53 Acute lymphoblastic leukemia, 69 Anacardiflavanone, 50 Acute myeloblastic leukemia, 52 Anatomic segmentectomy, 8 Acute myeloid leukemia (AML), 67 See also Non-small cell lung cancer Acute nephrotoxicity, 408 (NSCLC) M. Alaoui-Jamali (ed.), Alternative and Complementary Therapies 693 for Cancer, DOI 10.1007/978-1-4419-0020-3, Ó Springer ScienceþBusiness Media, LLC 2010 694 Subject Index Androgen receptor (AR) energy level, 66–67 abiraterone acetate and novel patient condition, 66 antiandrogens, 676 Centella asiatica, 34 antiandrogens, 677 Crocus sativus, 34 AR LBD in de novo cases of acute crystal structures of, 677 premyelocytic leukemia, domains and, 676 68–69 C-terminal helix-12 (H12), 674 diseases DBD, 673 Agnikarma, 37 HRPC, 677 Apachi, 36 and LBD, 673–674 Apunarbhav chikitsa, 37 mutations in AR genes, 676 Arbud, 36 NTD containing AF-1, 673 dietary advice and avoidance, signaling, 673 37 studies, 674 Galganda, 36 Angelica dahurica Granthi, 36 extract Gulma, 37 for upper respiratory tract, 474 Ksharkarma, 37 for viral and bacterial lesions, 37 infections, 474 marma, 37 Angong Huangti pills, 176 multiplicity or recurrence of ANITA, see Adjuvant Navelbine tumors, 37 International Trialist shodhan and shaman, 37 Association (ANITA) Vidradhi, 37 Anti angiogenesis therapy, 15 Eclipta alba, 34 agents, 7 etoposide, 33 Anticancer agents, 411 Lippia nodiflora, 34 Antimetabolites, DNA poisons, 6 management, drugs used Anti-VEGF monoclonal antibody, 7 Basant Malti, 68 APML, see Acute pro-myelocytic Kamadudha, 68 leukemia (APML) Navjeevan, 68 Ar-Curcumene, 58 Valipani, 68 Aroma therapy, 386 medicinal plants/formulations Ashwagandha, see Withania for cancer therapy, 35 somnifera L. Papaverum somniferum, 34 Auricular acupuncture, 129 physician, dilemma and Avastin, see Bevacizumab approach, 38 Ayurvedic medicine, 25, 405 podophyllotoxin, 33 art–science of health Pongamia pinnata, 34 Charak Samhita, 35 Poorva–Karma in cancer, 34 Sushrut Samhita, 35 prescription for management of Vaata, Pitta and Kapha, 35 cancer, 34 Vedic, 35 principles of camptothecin, 33 asthi and majja, 36 in cancer management, 34 Dhatus, 36 case records, 63–65 mamsa and meda, 36 Subject Index 695 mind–body relationship, 36 Qi and blood stagnate, 320 rasa and rakta, 36 Qi deficiency, 320 shukra, 36 and primary malignant tumor, 319 scientific basis for, 33 syndrome differentiation and Shorea robusta, 34 treatment, 320 taxol, 33 blood stasis obstruction vinca alkaloids, 33 internally, 325–326 excessive heat, 322–323 B heat accumulation in lung, Bai Zhi formulation, 219 321–322 Benign prostatic hyperplasia kidney deficiency, 329–331 (BPH) liver depression and Qi treatment with stagnation, 323–325 African potato, 470–471 spleen and stomach deficiency, Pygeum, 470–471 326–327 rye pollen, 470 unconsolidated kidney Qi, Saw palmetto, 470 327–329 stinging nettle, 470–471 TCM formulations Bevacizumab Chan Chu, 349 for metastatic cancers, 7 dietary therapy, 349 Bhilwanol A, see Catechol I Er Xian Tang, 336 Bhrigu-Samhita, 32 Fu Fang Er Ji Tang, 342–343 Bicalutamide, 676 Fu Fang Shan Zhi Tang, Biflavanones, 50 347–348 Bingdong zhidi mixture, 175 Jia Wei Wu Ling San, 341–342 Bing Pian, 214 Jie Du Li Shi Tang, 337 formulation for pain, 199 Lian Ji Di Huang Tang, liquor, 178 348–349 Bioactive molecules Long She Yang Quan Tang, from natural sources 335 bioactivity-directed Mi Ren Chi Dou Tang, 338 fractionation, 677 Qiang She Tang, 341 compound selection, 678 Sang She Tangh, 340 function-oriented synthesis, 679 San Jin Tang, 336–337 nine ginsenosides detection, 678 Xin Dan Pang Guang Tang, Panax ginseng study, 678 338–340 QCAR, 677–678 Ya Zao Feng Mi Wan, 335–336 TCM, 678 Zhi Pang Guang Ai Fang 1, virtual screening in, 678 343–344 Biological Diversity Act (2002), 538 Zhi Pang Guang Ai Fang 2, 344 Bioterrorism Act, 407 Zhi Pang Guang Ai Fang 3, 345 Bisdemethoxycurcumin, 58 Zhi Pang Guang Ai Fang 4, Black cohosh, 406, 408, 412 346 Bladder cancer treatment of complications etiology and pathogenesis infection, 333 heat evil damage, 320 outlet obstruction, 334 696 Subject Index Bladder cancer (cont.) Tian Zhu Huang, 365 uremia, 331–333 Tu Fu Ling, 365 types of, 320 Wu Gong, 365 Blood syndrome, 175 Xiao Yao Wan, 365 See also Liver cancer Ye Ju Hua, 365 Bortezomib Ye Ming Sha, 365 for multiple myeloma, 7 Yun Nan Bai Yao, 365 Botanical product, 403 syndrome differentiation and CDER’s botanical review team, 406 treatment See also Herbal products Bai Jiang Can, 352 BPH, see Benign prostatic Bai Jie Zi, 352 hyperplasia (BPH) Ban Xia, 352 Brain cancer Bing Qiu Zi, 352 with astrocytoma and Chi Shao Yao, 352 glioblastoma, 351 Chuan Xiong, 352 integration of TCM with Dang Gui, 352 conventional therapies, Dan Shen, 352 364 excessive heat in liver and Bai Hua She She Cao, 365 gallbladder, 358–359 Bai Jiang Can, 365 E zhu, 352 Bai Jiang Cao, 365 Hai Zao, 352 Ban Xia, 365 Huang Yao Zi, 352 Ban Zhi Lian, 365 internal obstruction of Chuan Bei Mu, 365 dampness and Chuan Xiong, 365 phlegm, 356–358 Ci Ji Li, 365 Kun Bu, 352 Da Huang Pian, 365 liver and kidney Yin Dang Gui, 365 deficiency, 355–356 Di Long, 365 liver deficiency, 359–361 Fang Feng, 365 Mu Li, 352 Fu Ling, 365 Nan Xing, 352 Gan Cao, 365 Qi and blood stagnation, Hai Fu Shi, 365 353–354 He Shou Wu, 365 San Leng, 352 Jin Qian Cao, 365 Shi Chang Pu, 352 Jin Yin Hua, 365 Shui Hong Hua Zi, 352 Kun Bu, 365 spleen and kidney Yang Men Shi Gun Tan Wan, 365 deficiency, 354–355 Mu Xiang, 365 Xiang Bei Mu, 352 Pu Gong Ying, 365 Yuan Zhi, 352 Quan Xie, 365 TCM formulations San Qi Fen, 365 Nao Liu Xiao Fang, Shan Ci Gu, 365 362–363 Sheng Di, 365 Nao Liu Yi Hao Fang, Shou Gong, 365 363–364 Tian Ma, 365 Nao Liu Yi Hao Fang 2, 364 Subject Index 697 sticky paste for external entwinement and obstruction application, 363 of phlegm and Qi, Xiao Liu Tang, 361 209–210 Yi Qi Hua Tan San, 361–362 liver depression and Qi treatment of complications stagnation, 209 central fever, 366–367 phlegm-dampness, 208 intracranial hypertension, 366 Qi and blood insufficiency, 208 Yang channels, 351 Qi deficiency, 208 Brain metastasis, 8 root pathogenesis, 208 Breast cancer, 52 soothe liver and regulate Qi, anthracyclines, 7 207 carboplatin and paclitaxel, 7 spleen deficiency, 208 diet therapy surgery-based combination Ju He Ru Mo Mi Yin, 218–219 therapy, 208 Pu Gong Ying Yuan Hu Yin, Yang deficiency, 208 219–220 zang-fu viscera, 208 Zao Jiao Ci Ju Pi Mi Yin, TCM for radiotherapy and 221–222 chemotherapy side endocrine therapy of Chinese effects medicine dermatitis, 217 Er Zhi Wan, 218 esophagitis, 216 Huang Jing, 218 internal heat, Yin deficiency, Liu Wei Di Huang Wan, 218 215 Lu Jiao Fen, 218 pneumonia, 215–216 Nu Zhen Zi, 218 Qi and Yin injury, 215 Xian Lin Pi, 218 stomatitis, 217–218 Xian Mao, 218 TCM formulations for, 206 etiology and pathogenesis from treatment of complications, 211 TCM perspective Bai Hua She She anxiety, 207 Cao, 212 Chong Channel, 207 Ban Zhi Lian, 212 Fu Ke Xin Fa Yao Jue, 207 breast ulcers, 213–214 Ge Zhi Yu Lun, 207 Bu Gu Zhi, 212 Ren Channel, 207 cancer pain, 214 worry and depression, 207 Chen Pi, 212 Yi Zong Jin Jian, 207 Chuan Jian Zi, 212 historical perspective Chuan Xin Lian, 212 Jiao Zhu Fu Ren Liang Fang, 206 Jin Gang Ci, 212 syndrome differentiation and Nu Zhen Zi, 212 treatment principle Pu Gong Ying, 212 accumulated phlegm-heat Qing Pi, 212 toxin, 208 Sang Zhi, 212 accumulation of blood stasis upper extremity swelling, and toxin, 210–211 212–213 dual deficiency of Qi and Yan Hu Suo, 212 blood, 211 Yi Yi Ren, 212 698 Subject Index Breast cancer (cont.) Carcinoembryonic antigen (CEA), 192 worldwide incidence Catechol I, 50 of, 205 CDK2, see Cyclin-dependent kinase 2 Breathing exercises, 379 (CDK2) Burning pain, 159 CEA, see Carcinoembryonic antigen Bu Zhong Yi Qi Tang formulation, 286 (CEA) Celastrol, 412 C Cell signalling and diseases CAM, see Complementary and protein-protein interactions in, 646 alternative medicine bioactive natural products, 653 (CAM) DOS, case for, 660 Camptosar1, see Irinotecan/CPT-11 FAK, 647–652 Canadian Intellectual Property Office and GRAF, 647 (CIPO),530 HDAC, 660–662 Canadian Patent Act, 549–550 human diseases, 647 Cancer-related fatigue (CRF) identification of, 652–655 concomitant factors of, 372–373 new technologies to screen for, conventional treatments, 373 655–660 integrative therapies, 373 protein kinase C (PKC), 648 biologically based practices, and role of naturally derived 374–377 molecules, 652 energy-based treatments,